



**EISAI LAUNCHES IN-HOUSE DEVELOPED  
NOVEL ANTICANCER AGENT LENVIMA®**

**[Notes to editors]**

**1. About Lenvima (lenvatinib mesylate)**

Discovered and developed in-house, Lenvima is an orally administered multiple receptor tyrosine kinase (RTK)